[Proglumetacin for a wide spectrum of activity in clinical medicine].
Twenty-nine patients with gouty arthritis, rheumatoid arthritis and osteoarthritis were treated as outpatients with proglumetacin, at different doses, during 5-30 days. In all patients with gout and osteoarthritis a significant improvement of pain and inflammatory symptoms was observed, together with a recovery of joint mobility. Seventy-nine per cent of patients with arthritis responded well or very well to the therapy. Tolerance was considered good or very good in 93% of patients.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D048909:Diabetes Complications; D004361:Drug Tolerance; D005260:Female; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D007210:Indoleacetic Acids / Q000627:therapeutic use*; D007592:Joint Diseases / Q000150:complications; D008297:Male; D008875:Middle Aged; D009765:Obesity; D009784:Occupational Diseases / Q000188:drug therapy; D010003:Osteoarthritis / Q000188:drug therapy*; D010300:Parkinson Disease / Q000150:complications
D007210:Indoleacetic Acids; C019541:proglumetacin
La proglumetacina per un'azione ad ampio spettro in clinica medica.